Chemotherapy-Related Neurotoxicity

Current Neurology and Neuroscience Reports

Volumn 16, Issue 9, 2016, Pages

  Taillibert, Sophie ^a   Le Rhun, Emilie ^b,c,d   Chamberlain, Marc C ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE OSCAR LAMBRET   (France)

^d UNIV LILLE   (France)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chemobrain; Chemotherapy; Chemotherapy induced peripheral neuropathy; Encephalopathy; Myopathy; Neurotoxicity

Indexed keywords

ASPARAGINASE; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DOCETAXEL; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NELARABINE; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PENTOSTATIN; PROCARBAZINE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE; VINFLUNINE;

ACUTE BRAIN DISEASE; ACUTE PANCEREBELLAR SYNDROME; ADVERSE OUTCOME; ARTERIAL ISCHEMIA; BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CEREBELLUM DISEASE; CHEMORADIOTHERAPY; CHRONIC BRAIN DISEASE; CLINICAL FEATURE; DISSEMINATED NECROTIZING LEUKOENCEPHALOPATHY; DRUG SAFETY; HUMAN; ISCHEMIA; LEUKOENCEPHALOPATHY; META ANALYSIS (TOPIC); MYOPATHY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEIZURE; SPINAL CORD DISEASE; SUBACUTE ENCEPHALOPATHY; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; CHEMICALLY INDUCED; MUSCLE DISEASE; NEUROTOXICITY SYNDROMES; PERIPHERAL NEUROPATHY;

BRAIN DISEASES; HUMANS; MUSCULAR DISEASES; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84979247535     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-016-0686-x     Document Type: Review

References (113)

1. Ganz PA, Dougherty PM. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. J Clin Oncol. 2016;34:649–52. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation and behavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.
2. Nudelman KN, McDonald BC, Wang Y, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34:677–83. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.
3. Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.
4. Chamberlain MC. Neurotoxicity of cancer treatment. Curr Oncol Rep. 2010;12:60–7.
5. Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies—a second look. InTech, 2012. pp. 39–60.
6. DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press; 2009. p. 447.
7. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.
8. Hansen H. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract. 2010;16:137–8.
9. Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.
10. Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.
11. Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–11.
12. Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.
13. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.
14. Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56.
15. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.
16. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.
17. Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797–804.
18. Ganz PA. Cancer treatment and cognitive function: chemotherapy is not the only culprit. Oncology (Williston Park). 2014;28(9):804–6.
19. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86.
20. Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–93.
21. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.
22. McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.
23. Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369–76.
24. Bower JE, Ganz PA, Irwin MR, et al. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol. 2013;31:1656–61.
25. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.
26. Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30:S99–108. An exploration of possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors. Cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging were performed. Onlyserum TNF levels was significantly correlated with increased memory complaints and with relatively diminished brain metabolism in the inferior frontal cortex.
27. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.
28. Deprez S, Vandenbulcke M, Peeters R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activations during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:20131–8. Evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy.
29. de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83.
30. de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.
31. McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28.
32. Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–53.
33. Ercoli LM, Castellon S, Petersen L, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. International Cancer and Cognition Task Force Meeting; Seattle, WA 2014.
34. Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psycho-Oncology. 2013;22:1043–9.
35. Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013;93:617–22.
36. Hunter AM, Kwan L, Ercoli LM, et al. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psycho-Oncology. 2014;23:713–5.
37. Moore HF, Parsons M, Yue G, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22:2127–31.
38. Herzig RH, Hines, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.
39. Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109:143–8.
40. Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;110:1698–9.
41. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87:694–9.
42. Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol. 2015;124(2):317–23.
43. Pruitt AA. Nervous system infections in patients with cancer. Neurol Clin N Am. 2003;21:193–219.
44. Rosenfeld MS, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–61.
45. Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006;108(2):150–6.
46. Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fi brinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the capelal study. Haematologica. 2008;93:1488–94.
47. Carreras E, Cahn JY, Puozzo C, et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30:2977–84.
48. Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71:164–7.
49. Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singap Med. 2007;48:e46–9.
50. Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathol Off J Jpn Soc Neuropathol. 2014;34:547–53.
51. Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122:391–8.
52. Graber JJ, Nolan CP. Myelopathies in patients with cancer. Arch Neurol. 2010;67:298–304.
53. Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol. 2010;97:425–7.
54. Tisi MC, Ausoni G, Vita MG, et al. Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7:e2015025.
55. Gollard RP, Selco S. Irreversible myelopathy associated with nelarabine in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2013;31:327–31.
56. Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011;86:98–101.
57. Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014;50:625–9.
58. Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–52.
59. Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.
60. Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.
61. Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol. 2012;259:1383–9.
62. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.
63. Garcia G, Atallah JP Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016.
64. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37.
65. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.
66. Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18.
67. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol. 2015. doi:10.1016/j.ygyno.2015.11.011. published online Nov 7.
68. Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70:18–25.
69. Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.
70. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.
71. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259:1936–43.
72. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2402–8.
73. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.
74. Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20:411–32.
75. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev. 2008;34(4):368–77. doi:10.1016/j.ctrv.2008.01.003.
76. Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–91.
77. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–14.
78. Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007;139:429–33.
79. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term(>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74:212–6.
80. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–8.
81. Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15:69–75.
82. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuoradiological features. Acta Neurol Scand. 2004;109:188–93.
83. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010;115:1343–50.
84. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.
85. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.
86. Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015. doi:10.1111/ecc.12407. published online Nov 4.
87. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039–52.
88. Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998;5(10):876–83.
89. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:1941–67. Evidence-based guidance on the optimum prevention and treatment approaches in the management of CIPN in adult cancer survivors.
90. Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.
91. Mols F, Beijers AJM, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2015;9:512–22.
92. Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. A randomized, double-blind, placebo-controlled crossover trial demonstrating effectiveness of duloxetine in the treatment of CIPN-related pain.
93. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.
94. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8, CD011091.
95. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.
96. Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015. doi:10.1111/jcpt.12297. published online June 7.
97. Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5, CD010769.
98. Papapetrou P, Kumar AJ, Muppuri R, Chakrabortty S. Intravenous lidocaine infusion to treat chemotherapy-induced peripheral neuropathy. Case Rep. 2015;5:154–5.
99. Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain moreeffectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag. 2012;43:87–95.
100. Xu WR, Hua BJ, Hou W, Bao YJ. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu. 2010;30:457–60.
101. Schroeder S, Meyer-Hamme G, Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4–7.
102. Abd-Elsayed A, Schiavoni N, Sachdeva H. Efficacy of spinal cord stimulators in treating peripheral neuropathy: a case series. J Clin Anesth. 2015. doi:10.1016/j.jclinane.2015.08.011. published online Sept 19.
103. Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.
104. Orsucci D, Pizzanelli C, Alì G, et al. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord NMD. 2012;22:767–70.
105. Pentsova E, Liu A, Rosenblum M, O’Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol. 2012;106:15–21.
106. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107–31.
107. Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70:320–3.
108. Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol. 2011;22(8):1763–9.
109. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.
110. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.
111. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23:597–602.
112. van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994;45:114–22.
113. Da Silva JA, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.